RU2018107929A - Комбинации и их использование - Google Patents
Комбинации и их использование Download PDFInfo
- Publication number
- RU2018107929A RU2018107929A RU2018107929A RU2018107929A RU2018107929A RU 2018107929 A RU2018107929 A RU 2018107929A RU 2018107929 A RU2018107929 A RU 2018107929A RU 2018107929 A RU2018107929 A RU 2018107929A RU 2018107929 A RU2018107929 A RU 2018107929A
- Authority
- RU
- Russia
- Prior art keywords
- combination according
- seq
- phosphoinositide
- preceding paragraphs
- sequence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Claims (18)
1. Синергическая комбинация, включающая в себя антитело, специфичное к CD19, где указанное антитело содержит участок HCDR1 с последовательностью SYVMH (SEQ ID NO: 1), участок HCDR2 с последовательностью NPYNDG (SEQ ID NO: 2), участок HCDR3 с последовательностью GTYYYGTRVFDY (SEQ ID NO: 3), участок LCDR1 с последовательностью RSSKSLQNVNGNTYLY (SEQ ID NO: 4), участок LCDR2 с последовательностью RMSNLNS (SEQ ID NO: 5), участок LCDR3 с последовательностью MQHLEYPIT (SEQ ID NO: 6) и ингибитор фосфоинозитид-3-киназы для применения в лечении неходжкинской лимфомы, хронического лимфоцитарного лейкоза и/или острого лимфобластного лейкоза.
2. Комбинация согласно п. 1, где антитело содержит вариабельную тяжелую цепь с последовательностью
EVQLVESGGGLVKPGGSL KLSCAASGYTFTSYVMHW VRQAPGKGLEWIGYINPY NDGTKYNEKFQGRVTISS DKSISTAYMELSSLRSED TAMYYCARGTYYYGTR VFDYWGQGTLVTVSS (SEQ ID NO: 10) и вариабельную легкую цепь с последовательностью DIVMTQSPATLSLSPGERA TLSCRSSKSLQNVNGNTYL YWFQQKPGQSPQLLIYRM SNLNSGVPDRFSGSGSGTE FTLTISSLEPEDFAVYYCMQ HLEYPITFGAGTKLEIK (SEQ ID NO: 11).
3. Комбинация согласно любому одному из предыдущих пунктов, где антитело содержит константный домен тяжелой цепи с последовательностью
ASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPA VLQSSGLYSLSSWTVPSSS LGTQTYICNVNHKPSNTK VDKKVEPKSCDKTHTCPP CPAPELLGGPDVFLFPPKP KDTLMISRTPEVTCVWDV SHEDPEVQFNWYVDGVE VHNAKTKPREEQFNSTFR WSVLTWHQDWLNGKEY KCKVSNKALPAPEEKTISK TKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKT TPPMLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVM HEALHNHYTQKSLSLSPGK (SEQ ID NO: 12).
4. Комбинация согласно любому одному из предыдущих пунктов, где антитело содержит константный домен легкой цепи с последовательностью
RTVAAPSVFIFPPSDEQLKS GTASWCLLNNFYPREAKV QWKVDNALQSGNSQESV TEQDSKD STYSLSSTLTLSKADYEKH KVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 13).
5. Комбинация согласно любому одному из предыдущих пунктов, где указанное антитело, специфичное к CD19, и указанный ингибитор фосфоинозитид-3-киназы вводят отдельно.
6. Комбинация согласно п. 5, где введение указанного антитела, специфичного к CD19, и указанного ингибитора фосфоинозитид-3-киназы разделено физически.
7. Комбинация согласно п. 5, где введение указанного антитела, специфичного к CD19, и указанного ингибитора фосфоинозитид-3-киназы разделено во времени.
8. Комбинация согласно любому одному из пп. 1-4, где указанное антитело, специфичное к CD19, и указанный ингибитор фосфоинозитид-3-киназы вводят вместе.
9. Комбинация согласно любому одному из предыдущих пунктов, где указанный ингибитор фосфоинозитид-3-киназы вводят до введения антитела, специфичного к CD19.
10. Комбинация согласно любому одному из предыдущих пунктов, где указанный ингибитор фосфоинозитид-3-киназы вводят после введения антитела, специфичного к CD19.
11. Комбинация согласно любому одному из пп. 1-4, где указанный ингибитор фосфоинозитид-3-киназы и антитело, специфичное к CD19, вводят одновременно.
12. Комбинация согласно любому одному из предыдущих пунктов, где указанный ингибитор фосфоинозитид-3-киназы представляет собой Иделалисиб.
13. Комбинация согласно любому одному из предыдущих пунктов для применения в лечении неходжкинской лимфомы, где неходжкинскую лимфому выбирают из группы, состоящей из фолликулярной лимфомы, малой лимфоцитарной лимфомы, лимфоидной ткани слизистых оболочек, лимфомы маргинальной зоны, диффузной крупноклеточной В-клеточной лимфомы, лимфомы Беркитта и лимфомы из клеток мантии.
14. Комбинация согласно любому одному из предыдущих пунктов для применения в лечении хронического лимфоцитарного лейкоза.
15. Комбинация согласно любому одному из предыдущих пунктов для применения в лечении острого лимфобластного лейкоза.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15181925 | 2015-08-21 | ||
| EP15181925.7 | 2015-08-21 | ||
| PCT/EP2016/069571 WO2017032679A1 (en) | 2015-08-21 | 2016-08-18 | Combinations and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018107929A true RU2018107929A (ru) | 2019-09-23 |
| RU2018107929A3 RU2018107929A3 (ru) | 2020-01-14 |
| RU2767063C2 RU2767063C2 (ru) | 2022-03-16 |
Family
ID=54010888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018107929A RU2767063C2 (ru) | 2015-08-21 | 2016-08-18 | Комбинации и их использование |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11224654B2 (ru) |
| EP (2) | EP3954388A1 (ru) |
| JP (4) | JP6862422B2 (ru) |
| KR (2) | KR20180042335A (ru) |
| CN (2) | CN107921129B (ru) |
| AU (3) | AU2016311136B2 (ru) |
| CA (1) | CA2995738A1 (ru) |
| CY (1) | CY1124706T1 (ru) |
| DK (1) | DK3337506T3 (ru) |
| ES (1) | ES2891336T3 (ru) |
| HR (1) | HRP20211291T1 (ru) |
| HU (1) | HUE056408T2 (ru) |
| IL (2) | IL257345B2 (ru) |
| LT (1) | LT3337506T (ru) |
| MX (2) | MX392561B (ru) |
| PL (1) | PL3337506T3 (ru) |
| PT (1) | PT3337506T (ru) |
| RS (1) | RS62260B1 (ru) |
| RU (1) | RU2767063C2 (ru) |
| SI (1) | SI3337506T1 (ru) |
| SM (1) | SMT202100541T1 (ru) |
| WO (1) | WO2017032679A1 (ru) |
| ZA (1) | ZA201801052B (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3954388A1 (en) * | 2015-08-21 | 2022-02-16 | MorphoSys AG | Combinations and uses thereof |
| PT3532098T (pt) | 2016-10-28 | 2021-06-17 | Morphosys Ag | Combinação de anticorpo anti cd19 com um inibidor bcl-2 e suas utilizações |
| FI3630177T3 (fi) | 2017-05-31 | 2023-10-18 | Morphosys Ag | Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle |
| JP7279011B2 (ja) | 2017-07-10 | 2023-05-22 | インターナショナル－ドラッグ－ディベロップメント－バイオテック | 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療 |
| KR20200030337A (ko) * | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| CN114786723A (zh) * | 2019-10-31 | 2022-07-22 | 莫佛塞斯公司 | 序贯抗cd19疗法 |
| JP2023551519A (ja) * | 2020-11-30 | 2023-12-08 | インサイト・コーポレイション | 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法 |
| MX2024007649A (es) * | 2021-12-22 | 2024-08-26 | Incyte Corp | Paradigma de tratamiento para una terapia con anticuerpos anti cumulo de diferenciacion (anti-cd19). |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| ATE502941T1 (de) | 2000-04-25 | 2011-04-15 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta |
| CA2422076A1 (en) | 2000-09-18 | 2002-03-21 | Idec Pharmaceutical Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| EP1461423B1 (en) | 2001-12-03 | 2008-05-14 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| US20080152649A1 (en) * | 2002-03-01 | 2008-06-26 | Xencor, Inc. | Optimized igf-1r antibodies and methods of using the same |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US7109304B2 (en) | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
| PT2612862T (pt) | 2004-05-13 | 2016-12-15 | Icos Corp | Quinazolinonas como inibidores de fosfatidilinositol 3-quinase delta humana |
| EP1899379B1 (en) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Cd19 antibodies and their uses |
| DK2270050T3 (da) | 2005-12-30 | 2013-08-12 | Merck Patent Gmbh | Anti-CD19-antistoffer med nedsat immunogenicitet |
| AU2007285976B2 (en) | 2006-08-14 | 2011-08-18 | Xencor, Inc | Optimized antibodies that target CD19 |
| CA2662340C (en) | 2006-09-08 | 2016-08-02 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| ES2599172T3 (es) | 2007-10-19 | 2017-01-31 | Seattle Genetics, Inc. | Agentes de unión a CD19 y usos de éstos |
| BRPI1005984A2 (pt) | 2009-02-23 | 2016-10-04 | Glenmark Pharmaceuticals Sa | anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit |
| US20120128586A1 (en) | 2009-06-24 | 2012-05-24 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
| HUE025759T2 (en) * | 2009-10-27 | 2016-04-28 | Amgen Res Munich Gmbh | Dosage regimen for administering a cd19xcd3 bispecific antibody |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| ES2730941T7 (es) * | 2010-10-22 | 2020-05-27 | Seattle Genetics Inc | Efectos sinérgicos entre los conjugados de conjugados anticuerpo-fármaco a base de auristatina e inhibidores de la ruta PI3K-AKT-mTOR |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| LT2744515T (lt) | 2011-08-16 | 2022-04-25 | Morphosys Ag | Kombinuota terapija su anti-cd19 antikūnu ir azoto garstyčiomis |
| CN103703027B (zh) | 2011-08-16 | 2018-01-12 | 莫佛塞斯公司 | 使用抗cd‑19抗体和嘌呤类似物的联合治疗 |
| MD20140100A2 (ru) | 2012-03-05 | 2015-01-31 | Gilead Calistoga Llc | Полиморфные формы (S)-2(1-(9Н-пурин-6-иламино)пропил)-5-фторо-3-фенилхинозолин-4(3Н)-она |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| MX356112B (es) | 2013-02-15 | 2018-05-15 | 3M Innovative Properties Co | Sistema y metodo para elaborar medios de filtracion plegados. |
| CN106794231A (zh) | 2014-06-16 | 2017-05-31 | 赞科股份有限公司 | 用于慢性淋巴细胞性白血病（cll）的治疗 |
| EP3302550B1 (en) | 2015-05-26 | 2019-08-28 | MorphoSys AG | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof |
| EP3954388A1 (en) | 2015-08-21 | 2022-02-16 | MorphoSys AG | Combinations and uses thereof |
| MD3465214T2 (ro) | 2016-05-30 | 2021-09-30 | Morphosys Ag | Metode de predicție a beneficiului terapeutic al terapiei anti-CD19 la pacienți |
| ES2874640T3 (es) | 2016-06-27 | 2021-11-05 | Morphosys Ag | Formulaciones de anticuerpos anti-CD19 |
| PT3532098T (pt) | 2016-10-28 | 2021-06-17 | Morphosys Ag | Combinação de anticorpo anti cd19 com um inibidor bcl-2 e suas utilizações |
| FI3630177T3 (fi) | 2017-05-31 | 2023-10-18 | Morphosys Ag | Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| KR20220007087A (ko) | 2019-05-03 | 2022-01-18 | 모르포시스 아게 | 제한된 수의 nk 세포를 갖는 환자에서의 항-cd19 치료제 |
| IL292181A (en) | 2019-10-31 | 2022-06-01 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| DK4051710T3 (da) | 2019-10-31 | 2025-12-15 | Incyte Corp | Antitumor-kombinationsterapi bestående af anti-cd19-antistof og gamma-delta-t-celler |
| CN114786723A (zh) | 2019-10-31 | 2022-07-22 | 莫佛塞斯公司 | 序贯抗cd19疗法 |
| TW202216193A (zh) | 2020-06-22 | 2022-05-01 | 德商莫菲西斯公司 | 包含抗CD19抗體及阻斷SIRPα-CD47先天免疫檢查點之多肽之抗腫瘤組合療法 |
| JP2023551519A (ja) | 2020-11-30 | 2023-12-08 | インサイト・コーポレイション | 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法 |
| IL303384A (en) | 2020-12-04 | 2023-08-01 | Morphosys Ag | Anti-CD19 combination therapy |
| MX2024007649A (es) | 2021-12-22 | 2024-08-26 | Incyte Corp | Paradigma de tratamiento para una terapia con anticuerpos anti cumulo de diferenciacion (anti-cd19). |
-
2016
- 2016-08-18 EP EP21186316.2A patent/EP3954388A1/en active Pending
- 2016-08-18 CN CN201680048061.2A patent/CN107921129B/zh active Active
- 2016-08-18 RS RS20211009A patent/RS62260B1/sr unknown
- 2016-08-18 SI SI201631293T patent/SI3337506T1/sl unknown
- 2016-08-18 JP JP2018508728A patent/JP6862422B2/ja active Active
- 2016-08-18 SM SM20210541T patent/SMT202100541T1/it unknown
- 2016-08-18 LT LTEPPCT/EP2016/069571T patent/LT3337506T/lt unknown
- 2016-08-18 DK DK16756997.9T patent/DK3337506T3/da active
- 2016-08-18 IL IL257345A patent/IL257345B2/en unknown
- 2016-08-18 EP EP16756997.9A patent/EP3337506B1/en active Active
- 2016-08-18 AU AU2016311136A patent/AU2016311136B2/en active Active
- 2016-08-18 HU HUE16756997A patent/HUE056408T2/hu unknown
- 2016-08-18 PT PT167569979T patent/PT3337506T/pt unknown
- 2016-08-18 RU RU2018107929A patent/RU2767063C2/ru active
- 2016-08-18 KR KR1020187007728A patent/KR20180042335A/ko not_active Ceased
- 2016-08-18 KR KR1020247011695A patent/KR102786010B1/ko active Active
- 2016-08-18 CA CA2995738A patent/CA2995738A1/en active Pending
- 2016-08-18 US US15/752,009 patent/US11224654B2/en active Active
- 2016-08-18 MX MX2018002241A patent/MX392561B/es unknown
- 2016-08-18 WO PCT/EP2016/069571 patent/WO2017032679A1/en not_active Ceased
- 2016-08-18 HR HRP20211291TT patent/HRP20211291T1/hr unknown
- 2016-08-18 CN CN202210502807.XA patent/CN115054697B/zh active Active
- 2016-08-18 IL IL297057A patent/IL297057B2/en unknown
- 2016-08-18 PL PL16756997T patent/PL3337506T3/pl unknown
- 2016-08-18 ES ES16756997T patent/ES2891336T3/es active Active
-
2018
- 2018-02-15 ZA ZA2018/01052A patent/ZA201801052B/en unknown
- 2018-02-20 MX MX2022006154A patent/MX2022006154A/es unknown
-
2021
- 2021-03-31 JP JP2021059383A patent/JP2021113194A/ja active Pending
- 2021-09-17 CY CY20211100817T patent/CY1124706T1/el unknown
- 2021-12-08 US US17/545,274 patent/US12194095B2/en active Active
-
2022
- 2022-04-28 AU AU2022202800A patent/AU2022202800B2/en active Active
-
2023
- 2023-03-30 JP JP2023054891A patent/JP2023093495A/ja active Pending
-
2024
- 2024-04-02 AU AU2024202109A patent/AU2024202109A1/en active Pending
- 2024-12-02 US US18/965,167 patent/US20250195646A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093012A patent/JP2025131697A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018107929A (ru) | Комбинации и их использование | |
| RU2017143166A (ru) | Комбинация антитела к CD19 и ингибитора тирозинкиназы брутона и их применение | |
| RU2014103490A (ru) | Комбинированная терапия с помощью антитела к cd19 и аналога пурина | |
| RU2014103492A (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом | |
| RU2019113370A (ru) | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения | |
| JP2023093495A5 (ru) | ||
| JP2018021031A5 (ru) | ||
| MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
| FI3110440T3 (fi) | Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| NZ731735A (en) | Anti-pd-1 antibodies and methods of use thereof | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| NZ740221A (en) | St2l antagonists and methods of use | |
| RU2015110981A (ru) | Комбинации и их применение | |
| PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
| JP2013542194A5 (ru) | ||
| JP2019533682A5 (ru) | ||
| PE20061324A1 (es) | Anticuerpos anti-il-6, composiciones, metodos y usos | |
| RU2013113933A (ru) | Антитело к cd38 и леналтдомид или бортезомиб для лечения множественной миеломы и nhl | |
| RU2018120695A (ru) | Связывающие молекулы, специфичные в отношении asct2, и их применения | |
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof |